India's drug regulator flagged Abhayrab batch KE25012 as substandard and potentially spurious after a field sample failed a potency test.
A government document seen by Reuters said the Central Drugs Laboratory also found discrepancies in labelling, artwork, and packaging versus a reference sample.
The vaccine is described as widely used, and state regulators were asked to maintain vigilance over the batch.
Indian Immunologicals Ltd and federal regulators did not respond to requests for comment.
The reporting says this is not the first such concern, with counterfeit-dose issues around the vaccine having surfaced before.
A quick read on shared facts, changing details, and different emphasis.
The reporting broadly agrees that India has flagged an Abhayrab rabies vaccine batch for possible quality and authenticity problems after laboratory testing. It also agrees that the matter centers on batch KE25012 and that the manufacturer and regulators did not provide comment.
What remains uncertain is whether the batch is ultimately confirmed as spurious or only substandard, since the account is based on a government document and an ongoing probe. The final regulatory outcome, and any wider implications for the vaccine, could change as more evidence emerges.
Swipe through the perspectives. Labels describe coverage framing, not truth or quality.
India's drug regulator flagged an Abhayrab rabies vaccine batch as substandard and potentially spurious after a field sample failed a potency test. The account says the Central Drugs Laboratory found differences in labelling and packaging compared with reference material, and that the federal regulator and manufacturer did not respond to requests for comment. It also notes that the same vaccine has faced counterfeit-dose concerns before. The story remains focused on the official probe rather than on confirmed enforcement action.
The latest eight dated reports, from earliest to newest.
Attributed summaries from official party channels. These are claims, not independent reporting or fact checks.
Scan each source take, then open the original article.
The Hindustan Times reports that India's drug regulator has flagged a batch of the Abhayrab rabies vaccine as substandard and potentially spurious after failing a potency test. According to a government document seen by Reuters, the Central Drugs Laboratory found differences in labelling and packaging compared to reference samples. The manufacturer, Indian Immunologicals Ltd, and federal regulators did not respond to requests for comment. This marks the second time in two years that concerns have been raised regarding counterfeit doses of the vaccine in India.
Devdiscourse reports that India's drug regulator has flagged a batch of the widely used Abhayrab rabies vaccine as substandard and potentially spurious following a failed potency test. A government document seen by Reuters details that the Central Drugs Laboratory found discrepancies in labelling, artwork, and packaging between a field sample and a reference sample. Indian Immunologicals Ltd and federal regulators did not respond to requests for comment regarding the investigation into batch KE25012.